DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more



Topical Clobetasol for the Treatment of Toxic Epidermal Necrolysis

Information source: University of California, Davis
ClinicalTrials.gov processed this data on August 23, 2015
Link to the current ClinicalTrials.gov record.

Condition(s) targeted: Toxic Epidermal Necrolysis

Intervention: Clobetasol 0.05% ointment (Drug)

Phase: Phase 1/Phase 2

Status: Not yet recruiting

Sponsored by: University of California, Davis

Official(s) and/or principal investigator(s):
Emanual Maverakis, MD, Principal Investigator, Affiliation: University of California, Davis

Overall contact:
Reason Wilken, MD, Phone: (916) 734-6760, Email: reason.wilken@ucdmc.ucdavis.edu

Summary

The primary objectives of this study are to investigate the efficacy and safety of topical steroid ointment (clobetasol 0. 05%) for the treatment of the cutaneous manifestations of toxic epidermal necrolysis (TEN).

Clinical Details

Official title: A Randomized Placebo Controlled Split-body Double-blind Phase II Clinical Trial to Investigate the Safety and Efficacy of Clobetasol 0.05% Ointment for the Treatment of Toxic Epidermal Necrolysis (TEN)

Study design: Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment

Primary outcome:

Safety (numeric cellulitis score)

Time to Cessation of Skin Detachment

Secondary outcome:

Time to 90% re-epithelialization

Percent Affected Surface Area

Percent Affected Surface Area Detached Skin

Detailed description: The experimental focus of this trial is thus to evaluate the safety and clinical outcomes of topical steroid (clobetasol 0. 05% ointment) for treatment of the cutaneous manifestations of toxic epidermal necrolysis (TEN). The design of the study is a randomized, placebo-controlled, double-blind split-body Phase II clinical trial in which clobetasol 0. 05% or placebo ointment will be topically applied to opposite arms for a period of fourteen days. The primary endpoints of the study are to determine the time to cessation of skin detachment in both groups as well as the safety of topical clobetasol to treat the cutaneous manifestations of TEN. Secondary outcome measures will evaluate efficacy by comparing the time to re-epithelialization and the percentage of affected skin between the clobetasol and placebo arms at various time points. An additional aim of the study is to characterize the genes expressed during the TEN disease state and any changes in gene expression following treatment with topical steroids, particularly those genes involved in the regulation of programmed cell death (apoptosis). This will be accomplished though molecular analysis of skin biopsy specimens obtained after treatment with clobetasol and placebo ointments. The specific hypothesis being tested is that two weeks of topical clobetasol will promote epidermal keratinocyte survival through suppression of TNF signaling, decreased granulysin expression and inhibition of other pro-apoptotic pathways resulting in shorter disease duration and decreased time to re-epithelialization.

Eligibility

Minimum age: 7 Years. Maximum age: 85 Years. Gender(s): Both.

Criteria:

Inclusion Criteria:

- Characteristic histological findings on diagnostic biopsy

- Clinical diagnosis verified by two independent physicians

- Greater than 10% affected body surface area (BSA)

- Ability to start treatment within seven days or less from the onset of erosions

- Actively worsening disease (enlarging area of involvement or new erosions occurring

over the last 24 hours)

- Patient Body Surface Area (BSA) > 1. 0 m2

- Reproductive age female patients must have a negative pregnancy test prior to

enrollment Exclusion Criteria:

- Patients will be excluded if they are < 7 or > 85 years of age.

- Patients who have documented:

- Uncontrolled infection (e. g. documented bacteremia)

- Malignancy

- Known prior immunodeficiency

- Pregnancy

- Concurrent use of systemic corticosteroids in the burn center greater than or

equal to 0. 5 mg/kg/day of prednisone or equivalent dose of similar medication.

- Greater than 70% eroded skin

- SCORETEN score >3 on hospital admission

- Patients will also be excluded if they have: active hepatitis and/or an ALT or AST

greater than four times the normal limits, or renal insufficiency with an estimated GFR<50 mL/min/1. 73m2.

Locations and Contacts

Reason Wilken, MD, Phone: (916) 734-6760, Email: reason.wilken@ucdmc.ucdavis.edu

Additional Information

Starting date: June 2015
Last updated: December 17, 2014

Page last updated: August 23, 2015

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017